Pamela Russell

Last updated

Pamela Russell
AM FAHMS
Personal details
DiedFebruary 2022
NationalityAustralian
Occupation Immunologist, medical researcher

Pamela J. Russell (died February 2022) [1] was an Australian academic researcher of immunology, bladder and prostate research. [2] Russell was awarded Membership of the Order of Australia (AM) for her research on prostate and bladder cancer in 2003. [3]

Contents

Biography

Russell was Emeritus Professor at the Institute of Health and Biomedical Innovation, Queensland University of Technology, based at the Translational Research Institute (Australia) [4] and adjunct professor, Centre for Advanced Imaging, University of Queensland. [5]

Education and training

Russell trained in immunology at Walter & Eliza Hall Institute, where she obtained an MSc with Sir Macfarlane Burnet. Subsequently, Russell completed a PhD with Sir Gustav Nossal, on studies of autoimmune diseases. [6] [7]

Russell's postdoctoral training was at the John Curtin School of Medical Research, Canberra, and then she moved to Sydney to take up a postdoctoral position at The Kolling Institute of Medical Research. [4]

Russell joined the APCRC – Q in 2009. [8]

Research

Russell's early work in Immunology on Systemic Lupus Erythematosus (SLE) showed that the immunosuppressive drug, cyclophosphamide, could be successfully used to treat animals with this disease, leading to its use in patients with SLE. Early work WEHI showed that T cells could kill cancer cells. [9] Further studies of autoimmunity were performed by Russell's group at the Kolling Institute specifically SLE. [10] but also some related work in rheumatoid arthritis and in ankylosing spondylitis and its association with HLA-B27. [11] [12]

Russell's focus of the work at the Kolling Institute was on autoimmunity, specifically Systemic Lupus Erythematosus (SLE), [13] but also some related work in rheumatoid arthritis and in ankylosing spondylitis and its association with HLAB27. [14] [15]

In 1984, Russell changed her research focus to cancer and, with Dr. Derek Raghavan, established the Urological Cancer Research Centre at Royal Prince Alfred Hospital/University of Sydney. Russell then directed the Oncology Research Centre (ORC), Prince of Wales Hospital from 1992 to 2010, as conjoint Professor of Medicine, University of New South Wales (UNSW).

Russell then moved to the Translational Research Institute and the Australian Prostate Cancer Research Centre in Queensland in 2012. [16] [17]

Awards

Selected Publications

Related Research Articles

<span class="mw-page-title-main">Autoimmunity</span> Immune response against an organisms own healthy cells

In immunology, autoimmunity is the system of immune responses of an organism against its own healthy cells, tissues and other normal body constituents. Any disease resulting from this type of immune response is termed an "autoimmune disease". Prominent examples include celiac disease, diabetes mellitus type 1, Henoch–Schönlein purpura, systemic lupus erythematosus, Sjögren syndrome, eosinophilic granulomatosis with polyangiitis, Hashimoto's thyroiditis, Graves' disease, idiopathic thrombocytopenic purpura, Addison's disease, rheumatoid arthritis, ankylosing spondylitis, polymyositis, dermatomyositis, and multiple sclerosis. Autoimmune diseases are very often treated with steroids.

<span class="mw-page-title-main">Ankylosing spondylitis</span> Type of arthritis of the spine

Ankylosing spondylitis (AS) is a type of arthritis from the disease spectrum of axial spondyloarthritis. It is characterized by long-term inflammation of the joints of the spine, typically where the spine joins the pelvis. With AS, eye and bowel problems—as well as back pain—may occur. Joint mobility in the affected areas sometimes worsens over time. Ankylosing spondylitis is believed to involve a combination of genetic and environmental factors. More than 90% of people affected in the UK have a specific human leukocyte antigen known as the HLA-B27 antigen. The underlying mechanism is believed to be autoimmune or autoinflammatory. Diagnosis is based on symptoms with support from medical imaging and blood tests. AS is a type of seronegative spondyloarthropathy, meaning that tests show no presence of rheumatoid factor (RF) antibodies.

<span class="mw-page-title-main">HLA-B27</span> Type of antigen

Human leukocyte antigen (HLA) B27 is a class I surface molecule encoded by the B locus in the major histocompatibility complex (MHC) on chromosome 6 and presents antigenic peptides to T cells. HLA-B27 is strongly associated with ankylosing spondylitis and other associated inflammatory diseases, such as psoriatic arthritis, inflammatory bowel disease, and reactive arthritis.

Spondyloarthritis (SpA), also known as spondyloarthropathy, is a collection of clinical syndromes that are connected by genetic predisposition and clinical manifestations. The best-known clinical subtypes are enteropathic arthritis (EA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and reactive arthritis (ReA). Spondyloarthritis typically presents with inflammatory back pain and asymmetrical arthritis, primarily affecting the lower limbs, and enthesitis, inflammation at bone-adhering ligaments, tendons, or joint capsules.

Etanercept, sold under the brand name Enbrel among others, is a biologic medical product that is used to treat autoimmune diseases by interfering with tumor necrosis factor (TNF), a soluble inflammatory cytokine, by acting as a TNF inhibitor. It has US Food and Drug Administration (FDA) approval to treat rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Tumor necrosis factor alpha (TNFα) is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha.

<span class="mw-page-title-main">Uveitis</span> Inflammation of the uvea of the eye

Uveitis is inflammation of the uvea, the pigmented layer of the eye between the inner retina and the outer fibrous layer composed of the sclera and cornea. The uvea consists of the middle layer of pigmented vascular structures of the eye and includes the iris, ciliary body, and choroid. Uveitis is described anatomically, by the part of the eye affected, as anterior, intermediate or posterior, or panuveitic if all parts are involved. Anterior uveitis (iridocyclitis) is the most common, with the incidence of uveitis overall affecting approximately 1:4500, most commonly those between the ages of 20–60. Symptoms include eye pain, eye redness, floaters and blurred vision, and ophthalmic examination may show dilated ciliary blood vessels and the presence of cells in the anterior chamber. Uveitis may arise spontaneously, have a genetic component, or be associated with an autoimmune disease or infection. While the eye is a relatively protected environment, its immune mechanisms may be overcome resulting in inflammation and tissue destruction associated with T-cell activation.

<span class="mw-page-title-main">HLA-B</span> Protein-coding gene in the species Homo sapiens

HLA-B is a human gene that provides instructions for making a protein that plays a critical role in the immune system. HLA-B is part of a family of genes called the human leukocyte antigen (HLA) complex. The HLA complex helps the immune system distinguish the body's own proteins from proteins made by foreign invaders such as viruses and bacteria.

<span class="mw-page-title-main">Leflunomide</span> Chemical compound

Leflunomide, sold under the brand name Arava among others, is an immunosuppressive disease-modifying antirheumatic drug (DMARD), used in active moderate-to-severe rheumatoid arthritis and psoriatic arthritis. It is a pyrimidine synthesis inhibitor that works by inhibiting dihydroorotate dehydrogenase.

Epratuzumab is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).

<span class="mw-page-title-main">Atrasentan</span> Chemical compound

Atrasentan is an experimental drug that is being studied for the treatment of various types of cancer, including non-small cell lung cancer. It is also being investigated as a therapy for diabetic kidney disease.

<span class="mw-page-title-main">Interferon alpha-1</span> Protein-coding gene in the species Homo sapiens

Interferon alpha-1 is a protein that in humans is encoded by the IFNA1 gene.

<span class="mw-page-title-main">Deoxyribonuclease gamma</span> Protein-coding gene in the species Homo sapiens

Deoxyribonuclease gamma is an enzyme that in humans is encoded by the DNASE1L3 gene. This gene's is located on chromosome 3's "p arm", i.e., short arm, between region 1, band 4, sub-band 3 and region 2, band 1, sub-band 1

<span class="mw-page-title-main">Lupus</span> Autoimmune disease in which the immune system attacks healthy tissue

Lupus, technically known as systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary among people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms.

James L. Gulley is an American cancer researcher and the Director of the Medical Oncology Service at National Cancer Institute.

Fibrous ankylosis is a condition that affects fibrous connective tissue causing a limited range of movement.

<span class="mw-page-title-main">Secukinumab</span> Monoclonal antibody against IL-17

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.

Alan Ebringer is an Australian immunologist, professor at King’s College in the University of London. He is also an Honorary Consultant Rheumatologist in the Middlesex Hospital, now part of the UCH School of Medicine. He is known for his research in the field of autoimmune disease.

<span class="mw-page-title-main">Jaccoud arthropathy</span> Medical condition

Jaccoud arthropathy (JA), is a chronic non-erosive reversible joint disorder that may occur after repeated bouts of arthritis. It is caused by inflammation of the joint capsule and subsequent fibrotic retraction, causing ulnar deviation of the fingers, through metacarpophalangeal joint (MCP) subluxation, primarily of the ring and little-finger. Joints in the feet, knees and shoulders may also get affected. It is commonly associated with systemic lupus erythematosus (SLE), and occurs in roughly 5% of all cases.

<span class="mw-page-title-main">Axial spondyloarthritis</span> Medical condition

Axial spondyloarthritis is a chronic, immune-mediated disease predominantly affecting the axial skeleton. The term itself is an umbrella term characterizing a diverse disease family united by shared clinical and genetic features, such as the involvement of the axial skeleton. The 2009 introduced term axial spondyloarthritis is a preferred term nowadays and substitutes the old term ankylosing spondylitis.

<span class="mw-page-title-main">Interleukin 40</span> Mammalian cytokine

Interleukin 40 (IL-40), also known with other name C17orf99, is a protein belonging to a group of cytokines called interleukins. It is encoded by a gene that does not belong to any cytokine superfamily. This cytokine is produced primarily by human expression tissues such as bone marrow and fetal liver, and its expression can be also induced in peripheral B cells after activation. IL-40 is involved in immunoglobulin A (IgA) production, and plays an important role in humoral immune responses and B cell homeostasis and development.

References

  1. ↑ "In Memory of Emeritus Professor Pamela Russell AM". Prostate Cancer Foundation of Australia. 3 March 2022. Retrieved 20 July 2024.
  2. ↑ "Pamela Russell". www.qut.edu.au. Retrieved 12 February 2019.
  3. ↑ "2003 Australia Day Honours List: AC, AO, AM". www.theage.com.au. 26 January 2003. Retrieved 12 February 2019.
  4. 1 2 "Pamela Russell". www.tri.edu.au. Retrieved 12 February 2019.
  5. 1 2 "Pamela Russell — Australian Prostate Cancer Research Centre - Queensland". www.australianprostatecentre.org. Archived from the original on 1 August 2017. Retrieved 6 March 2018.
  6. ↑ "Pamela Russell — Australian Prostate Cancer Research Centre - Queensland". www.australianprostatecentre.org. Retrieved 24 July 2024.
  7. ↑ "Pamela Russell | Translational Research Institute". www.tri.edu.au. Retrieved 24 July 2024.
  8. ↑ "Professor Pamela Russell — Prostate Cancer Collaborative Research Alliance". www.aus-canprostatealliance.org.
  9. ↑ Cameron, Fiona H.; Russell, Pamela J.; Easter, Joan F.; Wakefield, Denis; March, Lyn (1987). "Failure Of klebsiella pneumoniae antibodies to cross-react with peripheral blood mononuclear cells from patients with ankylosing spondylitis". Arthritis & Rheumatism. 30 (3): 300–305. doi:10.1002/art.1780300309. PMID   3551965.
  10. ↑ Cameron, F.; Russell, P.; Sullivan, J.; Geczy, A. (1983). "Is a Klebsiella plasmid involved in the aetiology of ankylosing spondylitis in HLA-b27-positive individuals?". Molecular Immunology. 20 (5): 563–566. doi:10.1016/0161-5890(83)90095-0. PMID   6348514.
  11. ↑ "Cell Surface Prostate Cancer Antigen for Diagnosis" . Retrieved 22 May 2019.
  12. ↑ "Minomic secures key patent in the United States and China". 5 September 2018. Retrieved 22 May 2019.
  13. ↑ Russell, Pamela J., and Alfred D. Steinberg. "Studies of peritoneal macrophage function in mice with systemic lupus erythematosus: Depressed phagocytosis of opsonized sheep erythrocytes in vitro." Clinical immunology and immunopathology 27, no. 3 (1983): 387-402.
  14. ↑ Cameron, Fiona H., Pamela J. Russell, Joan F. Easter, Denis Wakefield, and Lyn March. "Failure Of klebsiella pneumoniae antibodies to cross‐react with peripheral blood mononuclear cells from patients with ankylosing spondylitis." Arthritis & Rheumatism 30, no. 3 (1987): 300-305.
  15. ↑ Cameron, Fiona H., Pamela J. Russell, John Sullivan, and Andrew F. Geczy. "Is a Klebsiella plasmid involved in the aetiology of ankylosing spondylitis in HLA-B27-positive individuals?." Molecular Immunology 20, no. 5 (1983): 563-566.
  16. ↑ "Vale Emeritus Professor Pamela Russell AM FAHMS". Australian Academy of Health and Medical Sciences. 10 March 2022. Retrieved 12 March 2022.
  17. 1 2 "Remembering The Late Professor Pamela Russell AM". Funding Cancer Research | Cure Cancer. 2 March 2022. Retrieved 12 March 2022.
  18. ↑ "APCRC - Q Researcher Wins PCFA Award" . Retrieved 12 February 2019.
  19. ↑ "Fellowship of the Australian Academy of Health and Medical Sciences October 2015" (PDF). Retrieved 12 February 2019.
  20. ↑ "Pam Russell AM Alumni Excellence Award Health Winner" . Retrieved 12 February 2019.
  21. ↑ Singh, Preetiner Pal; Joshi, Swapna; Russell, Pamela J.; Verma, Nirupama D.; Wang, Xiaochun; Khatri, Aparajita (15 June 2011). "Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer". Clinical Cancer Research. 17 (12): 4006–4018. doi:10.1158/1078-0432.CCR-11-0248. ISSN   1557-3265. PMID   21531822.
  22. ↑ Hung, Tzong-Tyng; Chan, Jeffrey; Russell, Pamela J.; Power, Carl A. (2011). "Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model". PLOS ONE. 6 (5): e19389. Bibcode:2011PLoSO...619389H. doi: 10.1371/journal.pone.0019389 . ISSN   1932-6203. PMC   3095598 . PMID   21603655.
  23. ↑ Tang, Catherine; Russell, Pamela J.; Martiniello-Wilks, Rosetta; Rasko, John E. J.; Khatri, Aparajita (September 2010). "Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?". Stem Cells. 28 (9): 1686–1702. doi:10.1002/stem.473. ISSN   1549-4918. PMC   2996089 . PMID   20629172.
  24. ↑ Khatri, Aparajita; Husaini, Yasmin; Ow, Kim; Chapman, Jane; Russell, Pamela J. (1 April 2009). "Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines". Clinical Cancer Research. 15 (7): 2323–2334. doi:10.1158/1078-0432.CCR-08-2039. ISSN   1078-0432. PMID   19318483.
  25. ↑ Li, Yong; Song, Emma; Abbas Rizvi, Syed M.; Power, Carl A.; Beretov, Julia; Raja, Chand; Cozzi, Paul J.; Morgenstern, Alfred; Apostolidis, Christos; Allen, Barry J.; Russell, Pamela J. (1 February 2009). "Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates". Clinical Cancer Research. 15 (3): 865–875. doi:10.1158/1078-0432.CCR-08-1203. ISSN   1078-0432. PMID   19188157.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.